Moreover, SYK Y323 phosphorylation in AML has recently been correlated with an unfavorable prognosis (Boros et al., 2015), and activatory SYK phosphorylation (pY348) correlates with poor event-free and relapse-free survival in our AML patient cohort. This evidence concerns the gene SYK and acute myeloid leukemia.